PTCB Drug Interactions and Side Effects: duplicates, pairs and warnings

The interactions layer of Domain 1 (outline KA 1.2, KA 1.3 and KA 1.5): therapeutic duplication (the same ingredient or the same class twice), the five kinds of interaction the outline names (drug-drug, drug-dietary supplement, drug-laboratory, drug-nutrient and drug-disease), the seven mechanism families (additive CNS depression, serotonergic stacking, bleeding stacking, QT, CYP inhibition vs induction, chelation and potassium stacking), the high-yield pairs each with the label's own instruction, drug-supplement and drug-food interactions (St. John's wort, grapefruit, vitamin K, tyramine, chelators, alcohol), drug-laboratory monitoring, drug-disease cautions, the signature side effect of each class and the severe reactions a technician escalates, allergy vs intolerance, cross-sensitivity, the boxed warnings of the Top-200 drugs, and the pregnancy, pediatric, geriatric and narrow-therapeutic-index cautions.

What this topic actually asks of you

Domain 1 is Medications — 35% of the PTCE — and this topic owns three of its knowledge areas, the ones about what happens when drugs meet each other and when they meet a patient:

Therapeutic duplications

KA 1.2;

Common or life-threatening drug interactions and contraindications (e.g., drug-drug, drug-dietary supplement, drug-laboratory, drug-nutrient, drug-disease)

KA 1.3; and

Common or severe medication side effects, adverse effects, and allergies

KA 1.5. Together that is roughly an eighth of the exam (three of Domain 1's eight knowledge areas, and Domain 1 is 35% — PTCB does not publish per-knowledge-area weights), and the three share one idea: a drug is never given alone. It arrives with the patient's other prescriptions, their over-the-counter products, a supplement, a meal and a lab slip — and every one of those can change what it does.

The good news is that it is mostly pattern, not memory. Interactions come in a handful of mechanism families, and almost every pair the exam names is an instance of one: two drugs that both sedate, two that both bleed, two that both raise potassium, one that blocks the enzyme that clears the other. Learn the families and the pairs stop being a list.

What a technician does with this. Recognition and the right sentence — "this combination needs the pharmacist" — never the call itself. Every clinical decision in this topic ends in "refer to the pharmacist." You are the second pair of eyes on the counter: you spot the duplicate ingredient, the two NSAIDs, the opioid-and-a-benzo on the same profile, and you hand it to the pharmacist before it is filled. Knowing why it matters is what makes you look twice.

What this topic does not do. It does not teach how to dose around an interaction, and it does not ask you to memorize a database. The pairs below are the high-yield ones, each tied to the wording of a real FDA label, and every one is drawn from the Top-200 drug list this course is built on. Where a drug in a classic pair is not on that list, it is marked not in the Top-200 rather than dropped — the pair is still the exam's, even when one half is not on ours.

Two of the same thing: therapeutic duplication (KA 1.2)

Therapeutic duplication is the interaction a technician catches at the counter, before any enzyme is involved: the patient is already taking the drug being offered. It comes in two shapes.

One — the same ingredient in two products. Acetaminophen is the classic, because it is in hundreds of products, alone and in combination. The FDA's own advice is blunt: "Do not use more than one acetaminophen-containing product at a time" and "Acetaminophen is in many products. You could accidentally take too much if you use more than one product containing acetaminophen at a time" (FDA, Acetaminophen, content current 2025-08-14). The over-the-counter Drug Facts label carries the liver warning: "Severe liver damage may occur if you take more than 4,000 mg of acetaminophen in 24 hours with other drugs containing acetaminophen" (an OTC acetaminophen Drug Facts label, read via openFDA 2026-10-06). That is why the same ingredient shows up across a prescription combination opioid (a hydrocodone/acetaminophen tablet) and an over-the-counter tablet: 4,000 mg is a total over every acetaminophen product in 24 hours, not a per-product limit. Where a product's own Drug Facts label prints a lower limit — many extra-strength OTC labels say no more than 6 tablets in 24 hours, i.e. 3,000 mg — that lower number governs that product.

Two — the same class twice. Two of one drug is not the only duplication; two of one family is the same problem when the family shares an effect:

Two NSAIDs — ibuprofen plus naproxen, or either plus a prescription NSAID like meloxicam or diclofenac. They add in the same direction (stomach and kidney risk) without adding benefit. The ibuprofen label already carries a boxed cardiovascular and gastrointestinal warning for one NSAID.
An ACE inhibitor plus an ARB — lisinopril plus losartan. The lisinopril label names dual inhibition of the renin-angiotensin system as an interaction: "Increased risk of renal impairment, hypotension and hyperkalemia".
Two SSRIs — sertraline plus escitalopram, or an SSRI plus an SNRI. Two serotonergic drugs push toward serotonin syndrome, the mechanism family used below.
Two benzodiazepines — alprazolam plus lorazepam or diazepam: the same sedation, the same respiratory-depression risk, plus two dependence risks. Each carries the boxed warning about concomitant use with opioids.

How duplication shows up in the pharmacy — the DUR alert. When a claim is adjudicated the system runs a Drug Utilization Review and returns a conflict code. Therapeutic duplication is one of the coded conflict types; the technician's job is to read the alert, see the two products, and hand it to the pharmacist rather than overriding it. (The DUR codes themselves are covered in intervention reporting and infection control.) The technician does not decide that the duplication is fine; the technician surfaces it.

The five kinds of interaction (KA 1.3)

The outline names five types of interaction, and the exam tests them by name. The pattern is the same drug each time — only the second thing changes.

Question	The second thing is …	The classic example
In a drug–drug interaction, what is the second thing?	another medication (Rx or OTC)	warfarin + an NSAID; an opioid + a benzodiazepine
In a drug–dietary supplement interaction, what is the second thing?	a supplement, regulated as a food, not a drug	St. John's wort, an enzyme inducer
In a drug–nutrient / food interaction, what is the second thing?	a food or drink	grapefruit juice; vitamin K–rich greens; the tyramine in aged cheese
In a drug–laboratory interaction, what is the second thing?	a lab test rather than a body	a drug that changes a test result; the labs a drug requires
In a drug–disease interaction, what is the second thing?	a condition the patient has	a decongestant in a patient with high blood pressure

How drug–drug interactions happen: the seven mechanism families

Almost every drug–drug pair is one of a few mechanisms. Learn the family, and a pair you have never seen still tells you what to expect.

1. Additive CNS depression. Two drugs that each slow the central nervous system add together — more sedation, more respiratory depression. The extreme is an opioid plus a benzodiazepine, which carries a boxed warning: the benzodiazepine label's warning states that "Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death", and the opioid labels carry the mirror warning. Alcohol and other sedatives join the same stack. What to do: the pharmacist assesses and counsels; the technician never disposes of the pair on their own.

2. Serotonergic stacking. Two drugs that raise serotonin — an SSRI or SNRI, an MAOI, tramadol, triptans, linezolid (not in the Top-200) — can tip into serotonin syndrome (agitation, tremor, clonus, sweating, fever). The sertraline label makes MAOIs a contraindication — "Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue)… because of an increased risk of serotonin syndrome" — and names other serotonergic drugs to monitor. The MAOIs named above are not in the Top-200 (the list carries no MAOI), but the contraindicating rule is on every SSRI's label.

3. Bleeding stacking. Two drugs that each impair clotting or irritate the gut add to bleeding risk. The clopidogrel label lists it directly: "Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding". Citalopram's warnings say the same of "aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin and other anticoagulants" (citalopram label, read via openFDA 2026-10-06).

4. QT prolongation (at the concept level). Some drugs slow the heart's electrical reset and, put together, can trigger a dangerous rhythm (torsade de pointes). You are not asked to run the numbers; you are asked to recognize that two QT-prolonging drugs are a pair to flag. Citalopram's label is the Top-200 anchor: "Dose-dependent QTc prolongation, Torsade de pointes, ventricular tachycardia, and sudden death have occurred", and it names "other drugs that prolong the QTc interval" (citalopram label, read via openFDA 2026-10-06). The fluoroquinolones and macrolides are named QT-prolongers elsewhere on the list.

5. CYP inhibition versus induction. Most drugs are cleared by cytochrome P450 enzymes. Add a second drug that blocks one of those enzymes and the first drug's level rises; add one that induces (speeds up) the enzyme and the first drug's level falls. This is the family behind the most label interactions, and FDA keeps the authoritative rosters on one page — the Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers (FDA, content current 2023-06-05). Top-200 examples to place: oral ketoconazole is a strong CYP3A4 inhibitor (FDA table, same page); nirmatrelvir/ritonavir carries a boxed warning precisely because "PAXLOVID includes ritonavir, a strong CYP3A inhibitor"; fluconazole describes itself as "a moderate CYP2C9 and CYP3A4 inhibitor" and "a strong inhibitor of CYP2C19". The counterpoint: St. John's wort is an inducer, not an inhibitor — the amiodarone label lists it under "CYP450 Inducers" with "Reduced amiodarone serum levels".

6. Chelation. Certain drugs bind metal ions in the gut so neither is absorbed. The textbook victims are the fluoroquinolones, tetracyclines, levothyroxine and bisphosphonates, bound by the calcium, iron, magnesium or zinc in antacids, supplements and dairy. The levofloxacin label is explicit: "concurrent administration … with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin", and those agents "should be taken at least two hours before or two hours after" (levofloxacin label, read via openFDA 2026-10-06). Doxycycline warns that "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations". Levothyroxine's label lists "calcium carbonate, ferrous sulfate" among drugs that decrease T4 absorption, and alendronate warns that "calcium, antacids, or oral medications containing multivalent cations will interfere with absorption", instructing the patient to "wait at least one-half hour".

7. Potassium stacking. Two drugs that each raise serum potassium — an ACE inhibitor or ARB plus a potassium-sparing diuretic, a potassium supplement, or even an NSAID or trimethoprim — can push a patient into hyperkalemia. The spironolactone label spells out the loop: "Concomitant administration … with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia", naming ACE inhibitors, ARBs, NSAIDs, heparin, and trimethoprim, and advising "discontinue potassium supplementation in heart failure patients who start ALDACTONE" (spironolactone label, read via openFDA 2026-10-06).

The high-yield pairs, each with what the label says

Every row below is a high-yield pair, with the mechanism and the label's own instruction. Read the last column as the pharmacist's script — what you say out loud is "this needs the pharmacist." The label behind each row is cited in the page's sources, not printed here: a set ID is our filing number, and a reader cannot look one up.

Question	What happens (mechanism)	What the label says to do
What happens when an opioid is combined with a benzodiazepine?	Additive CNS and respiratory depression	Boxed warning on both; the benzo label: "may result in profound sedation, respiratory depression, coma, and death"
What happens when a nitrate is combined with a PDE-5 inhibitor (nitroglycerin or isosorbide + sildenafil/tadalafil/vardenafil — not in the Top-200)?	Blood pressure drops sharply — the label's "severe hypotension, syncope, or myocardial ischemia"	Contraindicated — "Do not use … in patients who are taking PDE-5 inhibitors"
What happens when warfarin is combined with an NSAID or an azole?	Bleeding stacks; azoles slow warfarin's clearance	Boxed warning: "Drugs, dietary changes, and other factors affect INR"; "more frequent INR monitoring … when starting or stopping other drugs, including botanicals"
What happens when an MAOI is combined with an SSRI/SNRI?	Serotonin syndrome	Contraindicated — SSRI labels: do not use with, or within 14 days of stopping, an MAOI
What happens when simvastatin meets a strong CYP3A4 inhibitor (ketoconazole, erythromycin, and ritonavir in Paxlovid; clarithromycin is not in the Top-200)?	Enzyme blocked, simvastatin level rises → myopathy/rhabdomyolysis	Contraindicated — "Concomitant use of strong CYP3A4 inhibitors … is contraindicated"
What happens when clopidogrel meets omeprazole or esomeprazole?	CYP2C19 inhibited → less active clopidogrel	"Avoid concomitant use of Plavix with omeprazole or esomeprazole" (avoid — not contraindicated)
What happens when methotrexate is combined with an NSAID or trimethoprim?	Methotrexate exposure rises → toxicity	The label's "Drugs that Increase Methotrexate Exposure" names "Aspirin and other nonsteroidal anti-inflammatory drugs" alongside the "oral antibiotics… penicillins… sulfonamides" it also lists; "monitor closely"
What happens when metronidazole meets alcohol?	Disulfiram-like reaction: "abdominal cramps, nausea, vomiting, headaches, and flushing"	"Discontinue consumption of alcohol … during and for at least three days after therapy"
What happens when digoxin is combined with amiodarone (or verapamil, diltiazem)?	Amiodarone raises digoxin; both slow the heart	Monitor heart rate and digoxin level — digoxin "has a narrow therapeutic index"
What happens when an SSRI is combined with an NSAID?	Serotonin plus antiplatelet effect → GI bleeding	The antiplatelet/SSRI labels list the combination as an increased bleeding risk
What happens when an ACE inhibitor/ARB meets potassium or a K-sparing diuretic?	Potassium stacking → hyperkalemia	"Check serum potassium levels"; "discontinue potassium supplementation in heart failure patients who start ALDACTONE" (spironolactone label)
What happens when an ACE inhibitor is combined with an ARB?	Dual RAS inhibition	"Increased risk of renal impairment, hypotension and hyperkalemia"
What happens when a fluoroquinolone meets calcium, iron or an antacid (or a tetracycline, levothyroxine, or a bisphosphonate)?	Chelation → both less absorbed	Separate by ≥ 2 hours (fluoroquinolone); bisphosphonate: wait ≥ 30 minutes
What happens when allopurinol meets amoxicillin or a thiazide?	Higher risk of a serious skin reaction	"may increase the risk of serious skin reactions… ampicillin and amoxicillin"; thiazides too
What happens when colchicine meets a strong CYP3A4/P-gp inhibitor?	Colchicine accumulates → "Fatal drug interactions have been reported"	Strong/moderate CYP3A4 and P-gp inhibitors: reduce the dose or avoid
What happens when a corticosteroid meets a potassium-wasting diuretic?	Additive potassium loss → hypokalemia	"observed closely for development of hypokalemia"

MAOIs are not in the Top-200; the pair is included because the SSRI labels name MAOIs directly, and the exam asks it in that form.

Drug–dietary supplement: St. John's wort

A dietary supplement is regulated as a food (under DSHEA), not as a drug — so it reaches the counter without the label sections a drug has, and the technician's move is to ask. The one the exam loves is St. John's wort, and the reason is that it is the rare example of an inducer. The amiodarone label lists it plainly under "CYP450 Inducers", with the clinical comment "Reduced amiodarone serum levels". The warfarin label makes the same point from the other side: "Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical (herbal) products, and inhibitors and inducers of CYP2C9, 1A2, or 3A4", and it warns to increase INR monitoring "when starting or stopping other drugs, including botanicals". The teaching sentence: an inducer lowers the level of the drug it interacts with, so the harm is often the drug quietly not working.

Drug–nutrient and drug–food

Question	What it does	The drugs (Top-200 ones in bold)
What does grapefruit (and Seville orange, pomelo, tangelo) do?	Blocks intestinal CYP3A4, so more drug enters the blood and stays longer — or, for a drug moved by transporters, less drug is absorbed	simvastatin, atorvastatin, nifedipine, cyclosporine, amiodarone, buspirone, budesonide; fexofenadine (less drug; not in the Top-200)
What do vitamin K–rich greens (kale, spinach, collards) do?	Antagonizes warfarin — a steady intake is fine, a swing is not	warfarin
What does tyramine in aged/fermented foods (aged cheese, cured meat, tap beer, fermented bean) do?	In a patient on an MAOI, a tyramine load can cause a hypertensive crisis	the MAOI (not in the Top-200)
What do dairy, calcium, iron and antacids do?	Chelation — binds the drug so neither is absorbed	ciprofloxacin, levofloxacin, doxycycline, levothyroxine, alendronate

The sources for that table: the warfarin row is the warfarin label's own warning, the tyramine row is the MAOI label (read via openFDA 2026-10-06), the grapefruit row is the FDA consumer update Grapefruit Juice and Some Drugs Don't Mix (content current 2021-07-01), and the chelation row is the labels of the five drugs named. | What does alcohol add for a patient on metronidazole, metformin or an opioid? | Adds to CNS depression; a disulfiram-like reaction with metronidazole; adds to the metformin lactic-acidosis risk | metronidazole ("during and for at least three days after therapy"); metformin ("Warn patients against excessive alcohol intake"); opioids and benzodiazepines by the boxed warning |

Grapefruit, the one to know cold. The FDA's consumer page names the exact classes — "Some statin drugs to lower cholesterol, such as Zocor (simvastatin) and Lipitor (atorvastatin)… Some drugs that treat high blood pressure, such as Procardia and Adalat CC (both nifedipine)… Some organ-transplant rejection drugs, such as Neoral and Sandimmune… (both cyclosporine)… Some anti-anxiety drugs, such as Buspir… (buspirone)… Some corticosteroids… (both budesonide)… Some drugs that treat abnormal heart rhythms… (both amiodarone)" (FDA, Grapefruit Juice and Some Drugs Don't Mix, content current 2021-07-01), and it shows the two directions — more drug in the blood for the statins, less for fexofenadine (not in the Top-200).

Drug–laboratory

Lab interactions run two ways: a drug can change a test result, or a drug can create the need for a test.

A monitoring lab a drug requires. The classic ones the exam names: INR for warfarin; serum digoxin and serum lithium (both narrow-therapeutic-index — lithium is not in the Top-200); TSH for levothyroxine; A1c and serum creatinine for the diabetes drugs and eGFR for metformin. Digoxin's own label says it "has a narrow therapeutic index, [so] increased monitoring of serum digoxin concentrations … is necessary when initiating, adjusting, or discontinuing drugs that may interact with digoxin".
A test the drug changes. The SGLT2-inhibitor labels warn of the incidental result: "SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests". A biotin supplement is the other classic — it can interfere with certain immunoassays — and it is named here as a known category rather than asserted with a citation, because no single label carries the full mechanism.

Drug–disease

A drug–disease interaction is a medicine that is fine in general and wrong for this patient.

Question	The drug to flag	Why (from the label/guidance)
Which drug must be flagged for high blood pressure?	a systemic decongestant (pseudoephedrine, phenylephrine — not in the Top-200)	They raise blood pressure — the one thing the patient is treating. The OTC Drug Facts: "Ask a doctor before use if you have heart disease, high blood pressure" (pseudoephedrine, openFDA 2026-10-06)
Which drug must be flagged for heart failure, CKD, or a history of ulcer?	an NSAID	Fluid retention and kidney strain; NSAIDs carry a boxed CV/GI warning
Which drug must be flagged for asthma?	a nonselective beta blocker (propranolol, carvedilol)	Blocking beta-2 receptors can trigger bronchospasm. The propranolol label lists "bronchial asthma" as a contraindication
Which drug must be flagged for BPH or narrow-angle glaucoma?	an anticholinergic (oxybutynin; diphenhydramine — not in the Top-200)	Urinary retention and rising eye pressure. The oxybutynin label: "contraindicated in patients with urinary retention, gastric retention … uncontrolled narrow-angle glaucoma"
Which drug must be flagged for kidney impairment?	metformin	Its boxed warning names renal impairment among the risk factors for lactic acidosis, and the label contraindicates it at eGFR below 30 mL/min/1.73 m² — "severe renal impairment" (metformin, openFDA 2026-10-06)
Which drug must be flagged for pregnancy?	an ACE inhibitor or ARB	Boxed warning: "When pregnancy is detected, discontinue … as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus"

Side effects, adverse effects and allergies (KA 1.5)

Three words that are not the same thing, and the exam asks you to keep them apart:

A side effect is a predictable effect of the drug at a normal dose — the dry cough of an ACE inhibitor, the drowsiness of a first-generation antihistamine. It is expected, and it is often why a drug is chosen or avoided.
An adverse effect is a harmful, unintended one — the same ACE inhibitor's angioedema, a fluoroquinolone's tendon rupture. The line between the two is severity and predictability, not mechanism.
An allergy is an immune response — hives, angioedema, anaphylaxis — and it is the one that goes on the allergy field of the patient's profile as a documented reaction. An intolerance (a predictable unpleasant effect, like nausea) and a side effect go in the notes, not the allergy field. Getting this wrong is a real harm: a patient marked "allergic to codeine" for an upset stomach may be denied a drug they can safely take, and a true anaphylaxis filed as a "side effect" may be dispensed again. When in doubt, refer to the pharmacist to classify it.

The signature side effect of each class

Question	The signature side effect	Escalate?
What is the signature side effect of ACE inhibitors?	A dry cough (bradykinin); angioedema is the serious one	angioedema → emergency
What is the signature side effect of ARBs?	Hyperkalemia, and angioedema far less often than with an ACE inhibitor — the point of the switch is the missing cough	high potassium → refer; angioedema → emergency
What is the signature side effect of Statins?	Muscle pain (myopathy); rhabdomyolysis is rare but serious	muscle pain + dark urine → refer
What is the signature side effect of SGLT2 inhibitors?	Genital mycotic infections; also volume depletion	refer
What is the signature side effect of Sulfonylureas?	Hypoglycemia	refer / treat
What is the signature side effect of metformin?	GI upset; lactic acidosis is the rare, boxed one	lactic acidosis → emergency
What is the signature side effect of Fluoroquinolones?	Tendinitis and tendon rupture (boxed), peripheral neuropathy, CNS effects	tendon pain → stop and refer
What is the signature side effect of GLP-1 receptor agonists?	Nausea, vomiting, diarrhea	refer
What is the signature side effect of Benzodiazepines?	Sedation; dependence; respiratory depression with opioids	with an opioid → emergency
What is the signature side effect of Opioids?	Constipation, sedation; respiratory depression	respiratory depression → emergency
What is the signature side effect of NSAIDs?	GI upset and bleeding; kidney strain	GI bleed → emergency
What is the signature side effect of Anticholinergics?	Dry mouth, urinary retention, confusion in the elderly	refer
What is the signature side effect of Corticosteroids?	Hyperglycemia, fluid retention, mood change	refer

The severe ones a technician escalates

These are the reactions that end the interaction at the counter and go straight to the pharmacist:

Angioedema / anaphylaxis — swelling of the lips, tongue or throat, difficulty breathing: an ACE inhibitor's serious reaction, and any drug's true allergy.
Stevens-Johnson syndrome / toxic epidermal necrolysis (SJS/TEN) — a blistering rash with skin detachment. The acetaminophen label warns that "Severe skin reactions may include skin reddening, rash, blisters, and detachment of the upper surface of the skin… even if you have taken acetaminophen in the past without any problems" (FDA, Acetaminophen, 2025-08-14). Any new rash with a new drug is a stop-and-refer.
Serotonin syndrome — agitation, tremor, clonus, sweating, fever, with two serotonergic drugs.
Lactic acidosis with metformin (boxed).
Respiratory depression with an opioid, especially with a benzodiazepine (boxed).
Long QT / torsade de pointes — fainting or a racing irregular pulse.

Cross-sensitivity: when one allergy predicts the next

Penicillin ↔ cephalosporin. The cephalexin label's warnings say: "Serious hypersensitivity (anaphylactic) reactions: Prior to use, inquire regarding history of hypersensitivity to beta-lactam antibacterial drugs. Discontinue the drug if signs or symptoms of an allergic reaction occur". The reaction risk is low but not zero, so refer to the pharmacist rather than deciding.
Aspirin ↔ other NSAIDs. A patient with aspirin-sensitive asthma may react to any NSAID. The ibuprofen label says such patients "should not be administered" ibuprofen and it is to be used "with caution in patients with preexisting asthma".
Egg allergy and vaccines. ACIP (2023; page updated 2024-09-05) is explicit: "ACIP recommends that all persons ages ≥6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used" (https://www.cdc.gov/vaccines/acip/recs/grade/influenza-egg-allergy-etr.html). The historical egg-avoidance rule is gone; the exam tests that you check the current guidance rather than an old habit.

The boxed warnings, across the Top-200

A boxed warning (a "black box") is the strongest warning FDA requires — the harm is serious or life-threatening, and the drug is still used because the benefit outweighs it. The list below is the drugs on our Top-200 whose own label carries one, grouped by topic. The machine-checked copy, with each drug's rank and SPL set ID, lives in the Top-200 drug list (the Boxed warnings section) and in the boxed-warnings list that goes with it.

Question	Top-200 drugs
Which drugs carry a boxed warning about Fetal toxicity (ACE inhibitors and ARBs)?	lisinopril, losartan, valsartan, irbesartan, olmesartan, benazepril, enalapril, ramipril, sacubitril/valsartan, and the HCTZ combinations
Which drugs carry a boxed warning about Suicidal thoughts and behaviors (young patients)?	sertraline, escitalopram, citalopram, fluoxetine, paroxetine, duloxetine, venlafaxine, bupropion, trazodone, mirtazapine, amitriptyline
Which drugs carry a boxed warning about Addiction, abuse, misuse; respiratory depression?	hydrocodone/acetaminophen, oxycodone, oxycodone/acetaminophen, morphine, tramadol, codeine (with acetaminophen)
Which drugs carry a boxed warning about Concomitant use with opioids; abuse, misuse and addiction; dependence and withdrawal (benzodiazepines)?	alprazolam, lorazepam, clonazepam, diazepam, temazepam
Which drugs carry a boxed warning about Cardiovascular thrombotic events; GI bleeding (NSAIDs)?	ibuprofen, naproxen, meloxicam, celecoxib, ketorolac (oral form only), diclofenac
Which drugs carry a boxed warning about Increased mortality in elderly patients with dementia-related psychosis (antipsychotics)?	quetiapine, risperidone, olanzapine, aripiprazole
Which drugs carry a boxed warning about Thyroid C-cell tumors (GLP-1 receptor agonists)?	semaglutide, dulaglutide, tirzepatide
Which drugs carry a boxed warning about Premature discontinuation; spinal/epidural hematoma (anticoagulants)?	apixaban, rivaroxaban
Which drugs carry a boxed warning about Tendinitis, tendon rupture, peripheral neuropathy, CNS effects (fluoroquinolones)?	levofloxacin, ciprofloxacin, ofloxacin (oral form only)
Which drugs carry a boxed warning about Bleeding risk?	warfarin
Which drugs carry a boxed warning about Diminished antiplatelet effect in CYP2C19 poor metabolizers?	clopidogrel
Which drugs carry a boxed warning about Complex sleep behaviors?	zolpidem
Which drugs carry a boxed warning about Pulmonary, hepatic and cardiac toxicity?	amiodarone
Which drugs carry a boxed warning about Embryo-fetal toxicity; severe adverse reactions?	methotrexate
Which drugs carry a boxed warning about Hepatotoxicity; pancreatitis; fetal risk?	divalproex
Which drugs carry a boxed warning about Serious skin rashes (SJS/TEN)?	lamotrigine
Which drugs carry a boxed warning about Lactic acidosis?	metformin
Which drugs carry a boxed warning about Congestive heart failure?	pioglitazone
Which drugs carry a boxed warning about Serious neuropsychiatric events?	montelukast
Which drugs carry a boxed warning about Not for obesity or weight loss?	levothyroxine
Which drugs carry a boxed warning about Carcinogenicity in animals?	metronidazole
Which drugs carry a boxed warning about Serious dehydration in patients under 2 years?	linaclotide
Which drugs carry a boxed warning about Marked elevation of supine blood pressure?	midodrine
Which drugs carry a boxed warning about Endometrial cancer; cardiovascular disorders; breast cancer; probable dementia?	estradiol
Which drugs carry a boxed warning about Abuse, misuse and addiction (stimulant)?	dextroamphetamine/amphetamine
Which drugs carry a boxed warning about Significant drug interactions (a strong CYP3A inhibitor)?	nirmatrelvir/ritonavir
Which drugs carry a boxed warning about Profound diuresis; electrolyte depletion?	bumetanide, furosemide
Which drugs carry a boxed warning about Clostridioides difficile-associated diarrhea?	clindamycin (oral, Cleocin HCl)
Which drugs carry a boxed warning about Hyperkalemia (with a potassium-sparing diuretic)?	triamterene/hydrochlorothiazide

Three names that do NOT belong on this list, and why. A separate pass over the boxed-warnings list excludes three rows a naive search would keep: oral hydrochlorothiazide and oral baclofen have no boxed warning of their own (the warnings openFDA returned came from a combination product and an intrathecal product respectively), and allopurinol's label carries the boxed-warning heading with no stated content. They are listed here so the exclusion is visible rather than silent.

Two rows say "oral form only." Ofloxacin and ketorolac are dispensed mostly as ophthalmic products (Ocuflox; Acular), and the ophthalmic labels carry no boxed warning — the warning belongs to the oral form, whose label is the one the source list below cites. The table names the form that carries the warning rather than letting a reader assume the eye drop does.

One name left this list. An earlier draft put buprenorphine/naloxone on the opioid row. The Suboxone and Zubsolv labels carry no boxed_warning field at all (openFDA, 2026-10-06), so it was removed from the table rather than kept on reputation.

Special populations: pregnancy, children, older adults

Pregnancy — the letters are gone. The old A/B/C/D/X letters were removed by FDA's Pregnancy and Lactation Labeling Rule (PLLR), which took effect June 30, 2015. The label now carries three narrative subsections — Pregnancy (8.1), Lactation (8.2) and Females and Males of Reproductive Potential (8.3) — instead of a letter (FDA, Pregnancy and Lactation Labeling Resources, content current 2025-03-10). The exam's tell: if a question offers a "Pregnancy Category C," that answer is out of date — the categories do not exist. The classic teratogens on our list keep their warnings in prose: an ACE inhibitor or ARB ("can cause injury and death to the developing fetus"), methotrexate (boxed "embryo-fetal toxicity" and contraindicated in pregnancy for non-neoplastic disease), warfarin, divalproex and finasteride/dutasteride (handling caution).

Children — three hard limits the labels state.

Codeine. The codeine sulfate label contraindicates it for "All children younger than 12 years of age" and for "Post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy" (codeine sulfate label). Tramadol carries the same kind of restriction; the teaching point is that the age limit is on the label, and it is a contraindication, not a caution.
Aspirin and Reye's syndrome. An OTC aspirin label's Drug Facts says: "Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product… these symptoms could be an early sign of Reye's syndrome, a rare but serious illness" (low-dose aspirin label, read via openFDA 2026-10-06).
Benzocaine teething products. The oral benzocaine label says "Do not use for teething in children under 2 years of age" and carries a methemoglobinemia warning (oral benzocaine label, read via openFDA 2026-10-06). OTC cough-and-cold products are likewise not for the youngest children; the teaching point is read the age line on the Drug Facts label.

Older adults — the AGS Beers Criteria, as a concept. The Beers Criteria is an expert list of medications to avoid in older adults (or use with caution), because age changes both the risk and the benefit. You are asked to recognize the concept and the high-yield examples — not to reproduce the table. The examples the exam leans on: first-generation antihistamines (diphenhydramine — not in the Top-200; hydroxyzine), long-acting benzodiazepines, strong anticholinergics, sliding-scale insulin, and long-term NSAIDs. The antipsychotic boxed warning ties in here: "Increased mortality in elderly patients with dementia-related psychosis" (quetiapine label, read via openFDA 2026-10-06).

Narrow therapeutic index drugs

A narrow therapeutic index (NTI) drug is one where the gap between a therapeutic dose and a toxic one is small — so a small change (a different brand, a new interacting drug, a missed lab) matters more. The exam's NTI set from our list, each with the label sentence behind it:

warfarin — INR-monitored; the label: "have a narrow therapeutic range (index)".
digoxin — "has a narrow therapeutic index".
levothyroxine — the label's warnings: "Levothyroxine sodium tablets has a narrow therapeutic index". TSH-monitored.

The practical consequence a technician handles: an NTI drug is where "same drug, different labeler" is a pharmacist's call, not a technician's swap. Refer to the pharmacist.

Two sentences to carry out of this topic

A drug is never given alone — check the whole profile, every time. And: know the mechanism family, and you can reason about a pair you have never seen; when the reasoning says "this matters," the answer is "refer to the pharmacist."

Where to go next

Next topic — dosage forms, doses and storage
The exam itself — the passing score, how many questions, and what makes the PTCB exam hard.

This topic sits inside Domain 1 — Medications, 35% of the exam — the outline's own weight, and PTCB publishes no per-knowledge-area split.

PTCE® is a registered trademark of the Pharmacy Technician Certification Board (PTCB). Elk Ridge Academy is not affiliated with or endorsed by PTCB.